Sam Slutsky
Stock Analyst at LifeSci Capital
(4.96)
# 111
Out of 4,421 analysts
593
Total ratings
52.4%
Success rate
43.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sam Slutsky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintained: Buy | $170 | $99.15 | +71.46% | 34 | Jun 16, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $67 | $32.43 | +106.60% | 40 | Jun 15, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $103 | $88.34 | +16.59% | 51 | Jun 15, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $60 | $45.10 | +33.04% | 37 | Jun 11, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $24 | $9.51 | +152.37% | 41 | Jun 6, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $125 | $72.34 | +72.80% | 20 | May 23, 2026 | |
| IMVT Immunovant | Rated: Buy | $42 → $45 | $35.34 | +27.33% | 70 | May 23, 2026 | |
| PYXS Pyxis Oncology | Maintained: Buy | $6 | $2.03 | +195.57% | 20 | May 23, 2026 | |
| IMUX Immunic | Maintained: Buy | $56 | $14.20 | +294.37% | 4 | May 16, 2026 | |
| ALXO ALX Oncology Holdings | Maintained: Hold | n/a | $1.53 | - | 28 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $21.23 | +111.96% | 5 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $108 | $61.08 | +76.82% | 32 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $31.74 | +32.33% | 25 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22.56 | $9.17 | +145.98% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $222 → $225 | $113.10 | +98.94% | 23 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 | $34.54 | +59.24% | 50 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $4.48 | +257.14% | 12 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $6 | $0.92 | +552.17% | 20 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.81 | - | 30 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $46 | $15.53 | +196.20% | 11 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.16 | $2.06 | n/a | 11 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7.5 | $6.25 | n/a | 22 | Dec 27, 2022 |
ABIVAX Société Anonyme
Jun 16, 2026
Maintained: Buy
Price Target: $170
Current: $99.15
Upside: +71.46%
Celldex Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $67
Current: $32.43
Upside: +106.60%
Spyre Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $103
Current: $88.34
Upside: +16.59%
Enliven Therapeutics
Jun 11, 2026
Reiterated: Buy
Price Target: $60
Current: $45.10
Upside: +33.04%
Olema Pharmaceuticals
Jun 6, 2026
Maintained: Buy
Price Target: $24
Current: $9.51
Upside: +152.37%
Oruka Therapeutics
May 23, 2026
Maintained: Buy
Price Target: $125
Current: $72.34
Upside: +72.80%
Immunovant
May 23, 2026
Rated: Buy
Price Target: $42 → $45
Current: $35.34
Upside: +27.33%
Pyxis Oncology
May 23, 2026
Maintained: Buy
Price Target: $6
Current: $2.03
Upside: +195.57%
Immunic
May 16, 2026
Maintained: Buy
Price Target: $56
Current: $14.20
Upside: +294.37%
ALX Oncology Holdings
May 16, 2026
Maintained: Hold
Price Target: n/a
Current: $1.53
Upside: -
May 16, 2026
Maintained: Buy
Price Target: $45
Current: $21.23
Upside: +111.96%
May 16, 2026
Maintained: Buy
Price Target: $108
Current: $61.08
Upside: +76.82%
May 16, 2026
Maintained: Buy
Price Target: $42
Current: $31.74
Upside: +32.33%
May 15, 2026
Maintained: Buy
Price Target: $22.56
Current: $9.17
Upside: +145.98%
May 9, 2026
Rated: Buy
Price Target: $222 → $225
Current: $113.10
Upside: +98.94%
May 9, 2026
Maintained: Buy
Price Target: $55
Current: $34.54
Upside: +59.24%
May 9, 2026
Maintained: Buy
Price Target: $16
Current: $4.48
Upside: +257.14%
May 9, 2026
Rated: Buy
Price Target: $6
Current: $0.92
Upside: +552.17%
Apr 29, 2026
Maintained: Hold
Price Target: n/a
Current: $1.81
Upside: -
Apr 20, 2026
Maintained: Buy
Price Target: $46
Current: $15.53
Upside: +196.20%
Dec 14, 2023
Maintained: Hold
Price Target: $1.16
Current: $2.06
Upside: n/a
Dec 27, 2022
Rated: Buy
Price Target: $7.5
Current: $6.25
Upside: n/a